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Introduction
Respiratory syncytial virus (RSV) is a major cause of 
respiratory morbidity and mortality in young children, 
accounting for over 33 million episodes of acute lower 
respiratory tract infection in children under 5 years old 
per year globally [1,2]. In the United Kingdom (UK), as in 
many other high-income countries, RSV bronchiolitis is 
the most common reason for hospitalisation in infants 
[3]. Infection in early life has been associated with an 
increased risk of wheeze-related illness throughout 
childhood [4].
There are currently no RSV vaccines available, although 
a number of candidates are in clinical trials [5]. Several 
factors related to the clinical and virological features 
of RSV challenge the design of an effective vaccina-
tion programme, including the very young age at which 
children are vulnerable to severe RSV morbidity (RSV-
related hospital admissions in the UK peak at 1 month 
of age [6,7]). Further, the short period of immunity 
induced by natural RSV infection [8], and the seasonal 
pattern of acute bronchiolitis admissions in temperate 
countries mean that a successful vaccine will need to 
induce a stronger immune response than that induced 
by natural infection [9,10]. In order to determine who 
should be vaccinated, and when, to effectively protect 
young children from infection, detailed data on risk of 
infection according to age and other characteristics, 
including family structure, are required.
Community-based serological surveys provide cru-
cial data for understanding the epidemiology of RSV, 
including the proportion of RSV-infected children who 
are asymptomatic, or who contact healthcare. A com-
munity cohort study of children in Kilifi, Kenya has 
provided insights into RSV dynamics that informed 
economic modelling of RSV vaccine programmes in low 
income settings [11,12]. A number of serological sur-
veys of RSV have been carried out in high income set-
tings [13-15]. However, these studies have limited data 
on risk factors for RSV infection in young children, such 
as family structure.
We describe the epidemiology of RSV during the first 
2 years of life in a cohort of children born in Bradford, 
UK. Using a unique longitudinal dataset combining 
serial serological data, parental questionnaires and 
routinely collected primary care and hospital records, 
we establish factors associated with maternally-
derived antibody concentrations, the proportion of 
children infected with RSV, their associated healthcare 
use, and risk factors for RSV infection by age.
Methods
Data source
We used data from the Born in Bradford (BiB) cohort 
study, a longitudinal multi-ethnic birth cohort of 12,453 
mothers and 13,773 children recruited in 2007–2011 
in Bradford [16]. Upon recruitment, women filled in a 
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baseline questionnaire; cord blood samples were col-
lected at birth. Cohort follow-up is via linkage to elec-
tronic health records, including maternity, primary care 
and hospital records for mothers and children. A sub-
set of mothers whose babies were born on or after 1 
March 2008 took part in the BiB Allergy and Infection 
(ALL-IN) sub-study [17], which collected additional 
questionnaires about the family and home environment 
from 2,562 children at age 1 and 2,067 at age 2 years. 
A total of 5 mL venous blood samples were collected 
from 1,884 (74%) and 1,623 (79%) children aged 1 and 
2 years old, respectively.
Inclusion criteria
We included all children from the ALL-IN study who 
had sufficient serial blood samples remaining at 
the age 1 and 2 years (490 children) [17]. To examine 
maternally-derived RSV antibody concentrations (that 
is, antibodies transferred from mother to baby during 
pregnancy), we additionally tested 210 cord samples 
from children in the BiB cohort, oversampling children 
born prematurely (resulting in 700 total cord blood 
samples). Sample size calculations are presented 
in Supplementary material 1.
Serological testing
Blood samples were tested for immunoglobulin G (IgG) 
antibody against RSV postfusion protein F (post F), and 
attachment protein G for RSV strands A (Ga) and B (Gb), 
referred to as IgG post-F, IgG Ga and IgG Gb, respec-
tively, throughout the paper, at the National Institute 
of Public Health and the Environment (Bilthoven, the 
Table 1
Description of variables included in analyses of mean maternally-derived antibody concentrations and risk of primary RSV 
infection at ages < 1 and 1–2 years, England, 2008–2013
Variable description Age at measurement Data source Variable derivation or categorisation
Annual quarter of birth Birth Maternity records January–March; April–June, July–September; October–December
Parity Birth Maternity records 0; 1; 2; ≥ 3
Ethnicity Birth Baseline questionnaire White British; Pakistani origin; other
Sex Birth Maternity records Boy/girl
Gestational agea Birth Maternity records < 35; 35–36; 37–40; ≥ 41 weeks
Birth weighta Birth Maternity records < 2,500; 2,500–3,499; ≥ 3,500 g
Gestational diabetesa Birth Maternity records Yes/no
History of hypertensiona Birth Maternity records
Yes/no 
 
(defined as presence of hypertension, pregnancy-
induced hypertension or preeclampsia)
Household sizeb





at 1 and 2 year





















at 1 and 2 year
Yes/no 
 










at 1 and 2 year
Rarely/once a week or more often
Age at blood sample 
measurementb





at 1 and 2 year
Age in months
RTI-related contact with healthcare 
during RSV season before blood 
measurementb
Any contact for < 1 and 
1–2 years olds
Linked primary care 
and hospital records Yes/no
ALL-IN: Allergy and Infection sub-study; RSV: respiratory syncytial virus; RTI: respiratory tract infection.
a Indicates variables used only for analyses of mean maternally-derived antibody concentrations.
b Indicates variables used only for analyses of risk of RSV infection.
Unless otherwise specified (footnotes a and b above), variables were used in both sets of analyses.
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Netherlands) using an RSV multiplex immunoassay 
(details described elsewhere [18]). In short, each of 
the three RSV antigens were coupled to distinct col-
our-coded activated carboxylated beads. Serum sam-
ples were diluted 1/200 and 1/8,000 in assay buffer 
containing phosphate-buffered saline with 1% bovine 
serum albumin and 0.1% Tween 20, incubated with the 
conjugated beads and subsequently incubated with 
R-phycoerythrin-labelled goat anti-human IgG anti-
body. The measurement of the samples was performed 
using a Bio-Plex 200 in combination with Bio-Plex 
Manager software version 6.1 (Bio-Rad Laboratories, 
Hercules, California, United States). The serum IgG 
antibody concentrations against post-F, Ga and Gb 
were quantified in arbitrary units/mL by interpolation 
from a five-parameter logistic curve of an in-house ref-
erence serum.
Outcomes
Our primary outcomes of interest were RSV IgG post-
F antibody concentrations, measured in cord blood, 
and infection status at age < 1 and 1–2 years old derived 
from IgG post-F levels. Our secondary outcomes were 
RSV IgG Ga and Gb antibody concentrations. All anti-
body concentrations were log-transformed for analysis.
Exposure variables
Study variables are described in  Table 1. All analyses 
included a priori annual quarter of birth (to account for 
seasonality of RSV, which peaks in early December in 
the UK), parity, ethnic group and child’s sex. For analy-
ses of maternally-derived antibody concentrations, we 
additionally included risk factors which could affect 
placental antibody transfer. For analyses of infec-
tion status at age < 1 and 1–2 years, we were addition-
ally interested in indicators of population mixing that 
we derived from responses to ALL-IN questionnaires 
at ages 1 and 2 years old, and age at measurement 
Figure 1
Distribution of loge RSV IgG post-F antibodies (A) at birth (n = 700 cord blood samples), (B) age 1 (n = 490 children) and (C) 
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IgG post-F: immunoglobulin G antibody against RSV postfusion protein F; loge: natural logarithm (base e); RSV: respiratory syncytial virus.
IgG post-F concentrations were quantified in arbitrary units/mL.
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(in months). We derived a binary variable indicating 
whether the child had had contact with primary or hos-
pital care due to lower or unspecified respiratory tract 
infection (RTI) during peak RSV season (November–
January) before blood measurement (from linked elec-
tronic health records, see Supplementary material 1 for 
a detailed definition).
Statistical analyses
We derived the number and proportion of children in 
our study and in the full ALL-IN cohort by risk factors at 
birth, age 1 and 2 years old.
Maternally-derived respiratory syncytial virus antibody 
concentrations
We derived mean maternally-derived loge  RSV IgG 
post-F antibody concentrations according to each risk 
factor category (listed in Table 1). We fitted a log-linear 
regression model to identify exposures associated with 
higher mean maternally-derived RSV IgG post-F levels. 
We determined factors associated with loge  RSV IgG 
post-F antibody concentrations in univariate analyses 
using analysis of variance (ANOVA). We included all risk 
factors significantly associated with placental antibody 
transfer in univariate analyses in the multivariable 
model (where p < 0.05); we excluded those that were 
not statistically significant in the mutually adjusted 
model from the final multivariable model according to 
Wald’s test (where p > 0.05).
Primary respiratory syncytial virus infection at ages 1 
and 2 years old
We applied a two-stage modelling strategy to determine 
risk factors for RSV infection. First, we used finite mix-
ture models (FMM) to classify children as RSV infected 
at age < 1 year and 1–2 years respectively according to 
their loge  RSV IgG post-F levels at age 1 and 2 years 
old. FMM is a well-established data driven method for 
classifying past exposure to infection [19,20]. FMM 
assume that the observed sample comes from distinct 
unobserved subpopulations. We expected two sub-
populations (infected/not-infected). The model was as 
follows:
Where (π1,π2  ) are probabilities of belonging to each 
subpopulation, and (f1,f2  ) are density functions for 
antibody concentrations in each subpopulation. 
For antibody concentrations at age 2, we allowed 
(π1,π2  ) to depend on observed antibody concentra-
tions at age 1. Details of FMM selection are described 
in Supplementary material 1.
For each child, we then derived a binary indicator of 
serological evidence of past RSV infection as:
Where pi  is the posterior probability of infection from 
FMM for child  i. Throughout the paper we refer to 
Table 2
Risk factors associated with increase in mean maternally-derived RSV IgG post-F antibody levels, England, 2008–2013 
(n = 683 children)a
Risk factor
Distribution of children included in the analyses by each 
risk factor (n = 683)b Adjusted ratios of geometric mean maternally-derived IgG 
post-F antibody levels (95% CI)c,d
N %
Gestational age (weeks)
 < 35 29 4.2 0.65 (0.48–0.89)
35–36 47 6.9 0.90 (0.70–1.16)
37–40 (baseline) 480 70.3 1 (baseline)
≥ 41 127 18.6 1.19 (1.01–1.39)
Parity
0 (baseline) 227 33.2 1 (baseline)
1 203 29.7 1.20 (1.03–1.40)
2 124 18.2 1.18 (0.99–1.42)
≥ 3 129 18.9 1.08 (0.90–1.30)
Time of birth
Jan–Mar 186 27.2 1.19 (1.00–1.42)
Apr–Jun 165 24.2 1.22 (1.02–1.46)
Jul–Sep 159 23.3 1.22 (1.03–1.46)
Oct–Dec (baseline) 173 25.3 1 (baseline)
CI: confidence interval; IgG post-F: immunoglobulin G antibody against RSV postfusion protein F; RSV: respiratory syncytial virus.
a The cohort included 700 children with cord blood samples, of whom 683 had complete information on all risk factors included in the final 
analyses of maternally-derived antibody concentrations.
b The number and percentages of children, per risk factor category included in the final model, are presented.
c The exponentiated results from the loge-linear model (mutually adjusted for all variables in the table), reflecting proportional change in 
maternally-derived IgG post-F levels for each risk factor category relative to the baseline are shown.
d The mean maternally-derived RSV IgG post-F antibody concentration at baseline (gestational age of 37–40 weeks, parity of 0 and birth in 
October–December) was 268 arbitrary units/mL (95% CI: 229–314 arbitrary units/mL).
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presence of serological evidence of past RSV infection 
from the FMM as ‘RSV infection’. We calculated the 
number and proportion of children who acquired pri-
mary RSV infection aged < 1 year and 1–2 years old. We 
derived the proportion of infected (seropositive) and 
seronegative children who had RTI-related contact with 
healthcare during peak RSV season. We compared the 
distribution of risk factors in RSV-infected and never-
infected children by age.
We estimated risk ratios (RR) for primary RSV infec-
tion at age < 1 and 1–2 years old using Poisson regres-
sion models with robust error variances calculated 
using sandwich estimators [21]. We decided a priori to 
include child’s age at blood sample measurement and 
annual quarter of birth, sex and ethnicity in the mod-
els. We added all indicators of population mixing to the 
model (listed in Table 1). Then we removed those that 
were not statistically significant according to Wald’s 
test (where p > 0.05).
Sensitivity analyses
Infections in infants aged < 6 months old may not be 
detectable using serology, as young infants do not 
mount an antibody response to infection (or their 
response might be ‘masked’ by maternally-derived 
antibodies) [22-24]. We therefore repeated all analyses 
after re-classifying children who had RTI-related con-
tact with healthcare aged < 6 months during RSV sea-
son (October–February) and during peak RSV season 
(November–January) as infected at age < 1 year.
To account for possible misclassification of infection 
status arising from using a cut-off for the posterior prob-
ability of infection from the FMM, pi    , we simulated the 
infection status for each child i as a random draw from 
Bernoulli distribution with pi  taken as the probability 
of success. We then re-calculated RR for primary infec-
tion. We repeated this 50 times and pooled estimates 
of RRs using Rubin’s rules for the parameter estimates 
and variance-covariance matrix [25]. We repeated all 
analyses using loge  RSV IgG Ga and Gb. All analyses 
were carried out using Stata version 15.
Figure 2
Distribution of primary RSV infections in children by age at first infection and severity of infection (as indicated by contact 
with healthcare), England, 2008–2013 (n = 490 children)
Serological evidence of any RSV infection by age 2 years:  
422/490 children (86% of sampled children; 95% CI: 83–89%) 
 
258 children 
53% (95% CI: 48–57%) of sampled children 
61% (95% CI: 56–66%) of ever infected children 
164 children 
33% (95% CI: 29–38%) of sampled children 
39% (95% CI: 34–44%) of ever infected children 
99 children 
20% (95% CI: 17–24%) of sampled children  
38% (95% CI: 34–43%) of children 
first infected at age <1 year 
58 children  
12% (95% CI: 9.1–15%) of sampled children  
35% (95% CI: 28–43%) of children  
first infected at age 1–2 years 
Serological evidence of rst infection at age <1 year:  
 
Serological evidence of rst infection at age 1–2 years:  
 
<5 children 
<1% (95% CI: 0.3–2.4%) of sampled children 
<3% (95% CI: 1.0–7.0%) of children 
first infected at age 1–2 years 
 
9 children 
1.8% (95% CI: 0.8%–3.5%) of sampled children 
3.5% (95% CI: 1.6%–6.5%) of children 
first infected at age <1 year 
 
128 children 
26% (95% CI: 22–30%) of sampled children
50% (95% CI: 43–56%) of children  
first infected at age <1 year 
Contacted primary or hospital care  during RSV season (October–February) prior to blood measurement 
 79 children  
16% (95% CI: 13–20%) of sampled children
48% (95% CI: 40–56%) of children  
first infected at age 1–2 years 
Admitted to hospital during peak RSV season (November–January) prior to blood measurement 
 
Contacted primary or hospital care during peak RSV season (November–January) prior to blood measurement 
 
CI: confidence interval; RSV: respiratory syncytial virus.
Left-hand side shows the number and proportion of children first infected aged < 1 year old, right-hand side show the proportion of children 
first infected aged 1–2 years old (that is, they were never infected at age < 1). We present the number of children who contacted healthcare 
using a broad definition of RSV season (October–February) and peak RSV season (November–January).
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Ethical statement
Parents in BIB and ALL-IN studies have given informed 
consent for use of data and stored blood samples for 
research studies. The ALL-IN study has been approved 
by the Bradford Research Ethics Committee, reference 
number 08/H1302/21.
Results
The cohort included 700 children with cord blood sam-
ples, of whom 683 (98%) had complete information on 
all risk factors included in the final analyses of mater-
nally-derived antibody concentrations. A total of 490 
children had blood samples measured at both age 1 and 
2 years old, of whom 477 (97%) had complete informa-
tion on risk factors included in the final analyses of risk 
factors for primary RSV infection. Over half of children 
(55%; 384/700) were of Pakistani origin compared to 
49% (1,251/2,562) in the ALL-IN study (Supplementary 
Table S3). Reflecting oversampling of preterm babies, 
11% (76/700) of the children in the cohort were born 
prematurely vs 5.8% (149/2,562) in the ALL-IN study 
and a third were first-born (227/700) compared to 
36%, 920/2,562 in the ALL-IN study. Mean age at first 
ALL-IN questionnaire was 13.1 months (95% confidence 
interval (CI): 13.0–13.2 months,  Supplementary Table 
S4), and at second questionnaire was 25.6 months 
(95% CI: 25.5–25.7 months). Maternally-derived anti-
bodies showed an approximately normal distribution; 
at age 1 antibody concentrations were equally distrib-
uted around two peaks; at 2 years old, the majority 
of observations were centred around the higher peak 
(Figure 1).
Maternally-derived respiratory syncytial virus 
antibody concentrations
Gestational age, parity and annual quarter of birth 
were significantly associated with maternally-derived 
RSV antibody concentrations (see Supplementary Table 
S5 for detailed results). Children born at < 35 gestational 
weeks had 35% lower, and children born at ≥ 41 weeks 
had 19% higher, mean maternally-derived IgG post-F 
levels compared with children born at 37–40 weeks 
(Table 2). Presence of 1–2 older siblings compared with 
no older siblings was associated with 18–20% higher 
Table 3
Adjusted risk ratios for primary RSV infection at age 1 and 2 years old by risk factor, England, 2008–2013 (n = 477)a
Risk factor Adjusted risk ratios for primary RSV infection at age < 1 year old (95% CI)b
Adjusted risk ratios for primary RSV infection 
at age 1–2 years old (95% CI)b
Number of children included in the model 477 229
Number of infected children 248 162
Sex
Male (baseline) 1 (baseline) 1 (baseline)
Female 1.07 (0.91–1.27) 1.12 (0.95–1.32)
Ethnic group
White British (baseline) 1 (baseline) 1 (baseline)
Pakistani origins 1.23 (0.98–1.55) 0.88 (0.73–1.05)
Other 1.27 (0.95–1.69) 1.01 (0.80–1.28)
Annual quarter of birth
Jul–Sep (baseline) 1 (baseline) 1 (baseline)
Oct–Dec 1.57 (1.19–2.08) 1.23 (1.02–1.48)
Jan–Mar 1.57 (1.18–2.09) 1.12 (0.89–1.41)
Apr–Jun 1.63 (1.22–2.18) 0.77 (0.54–1.09)
Parity
0 (baseline) 1 (baseline) 1 (baseline)
1 1.49 (1.18–1.87) 1.27 (1.04–1.56)
2 1.22 (0.93–1.60) 1.20 (0.93–1.56)
≥ 3 1.38 (1.06–1.79) 1.34 (1.05–1.70)
Attending any formal childcare
No (baseline) 1 (baseline)
Not included in the final model
Yes 1.36 (1.09–1.69)
Age at measurementc 1.08 (1.00–1.16) 1.02 (0.96–1.08)
CI: confidence interval; RSV: respiratory syncytial virus.
a Of 490 children whose blood samples were tested for immunoglobulin G antibody against RSV postfusion protein F, 477 (97%) had complete 
information for the analysis of risk factors for primary RSV infection at age <1 year old. Of these, 229 had not experienced an infection in 
infancy and were included for the analysis of risk factors for primary RSV infection at age 1–2 years.
b Risk ratios for primary RSV infection by each risk factor were estimated from Poisson regression models with robust error variances 
calculated using sandwich estimator.
c Age at measurement was centred around 12 months for risk ratios for primary RSV infection at age < 1 year, and around 24 months for risk 
ratios for primary RSV infection at age 1–2 years.
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mean maternally-derived antibody concentrations, 
and ≥ 3 siblings with 8% higher levels. Children born 
outside October–December had 19–22% higher mean 
maternally-derived antibody concentrations than chil-
dren born during these months.
Primary respiratory syncytial virus infection at 
ages 1 and 2 years old
By age 1 year, 258/490 children 
(53%; 95% CI: 48–57%,  Figure 2) had serological 
evidence of past RSV infection, 99 of whom had 
RTI-related contact with primary or hospital care 
in November–January (38% of RSV infected chil-
dren; 95% CI: 34–43%); nine had had an RTI-related 
hospitalisation. Of 232 children who were RSV seron-
egative at age 1, 48 (21%; 95% CI: 16–26%) had RTI-
related contact with healthcare in November–January 
(of whom 29 were aged < 6 months old). A further 164 of 
490 children had serological evidence of primary RSV 
infection at age 1–2 years old (33%; 95% CI: 29–38%), 
58 of whom had RTI-related contact with primary or 
hospital care in November–January (35% of children 
first infected at age 1–2; 95% CI: 28–43%). A propor-
tion of 68/490 children (14%; 95% CI: 11–17%) had 
no evidence of RSV infection by age 2, of whom 13 
(19%; 95% CI: 11–30%) had RTI-related contact with pri-
mary or hospital care in November–January.
Factors associated with an increased risk of RSV infec-
tion aged < 1 year old were annual quarter of birth, 
number of older siblings, and attending formal child-
care (Table 3, see Supplementary Table S6 for detailed 
analyses). Children with one older sibling had 49% 
higher risk of infection in infancy relative to children 
with no older siblings. Having two, or more than two, 
siblings increased the risk of infection by 22% and 
38%, respectively, compared to no siblings. Children 
who attended formal childcare had 36% higher risk of 
infection compared with children who did not attend 
formal childcare. The risk of infection was 57–63% 
higher for children born during or after RSV season 
(i.e. in October–June). The risk of primary infection 
at age 1–2 years old was greater for children with 
siblings compared with children with no siblings, and 
for children born during the RSV season (October–
March, Table 3).
Sensitivity analyses
We identified an additional 40 children who had RTI-
related contact with healthcare in October–February 
aged < 6 months. After re-classifying these chil-
dren as infected in infancy, we estimated that 61% 
(299/490; 95% CI: 57–65%) of children were RSV-
infected aged < 1 year, 28% (137/490; 95% CI: 24–32%) 
were newly infected aged 1–2 years old and 11% 
(54/490; 95% CI: 8–14%) had no evidence of RSV infec-
tion by their second birthday. RRs did not change sub-
stantially (Supplementary Tables S7 and S8), apart 
from the effect of annual quarter of birth on risk of pri-
mary RSV infection in infancy, which reduced substan-
tially for all annual quarters compared with children 
born in July–September. Sensitivity analyses included 
a higher number of RSV infections in the baseline cate-
gory (born in July–September) compared with the main 
analyses, leading to a smaller, non-significant effect of 
annual quarter of birth. The pooled estimates from 50 
simulated outcomes were consistent with results from 
the main analysis.
Analyses of maternally-derived IgG Ga and Gb showed 
similar results to those for IgG post-F (Supplementary 
Table S9). The indicator of RSV infection in infancy 
derived using each IgG post-F, Ga and Gb agreed for 
58% (284/490) of children, 32% (156/490) showed 
agreement between IgG post-F and either Ga or Gb 
antibodies (Supplementary Table S10). Since IgG Ga 
and Gb antibodies are less immunogenic than IgG 
post-F [18], we did not re-calculate RRs using RSV infec-
tion indicators from these models (see Supplementary 
material 2 for details).
Discussion
By the end of their first year of life, 53% of children 
experienced at least one RSV infection, 38% of whom 
had RTI-related contact with healthcare during peak 
RSV season. A further 33% of children experienced 
their first RSV infection aged 1–2 years old, 35% of 
whom had RTI-related contact with primary or hospi-
tal care during the RSV season. One in seven children 
had no evidence of RSV infection by age 2. Having older 
siblings, attending formal childcare and birth between 
October and June were predictive of RSV infection at 
age < 1. Having older siblings contributed to increased 
risk of RSV infection between 1 and 2 years. Children 
born at later gestational ages, in families with older 
siblings and after the first half of the RSV season 
(October–December) had higher mean maternally-
derived antibody concentrations.
Strengths and limitations
We used a unique collection of longitudinal blood 
samples in children up to 2 years of age, linked to rich 
questionnaire data with information on risk factors in 
the child’s family and home environment. Routinely 
collected electronic health records from primary care 
and hospitals provided us with indicators for more 
severe symptomatic RTIs leading to healthcare contact. 
Infection status was derived from antibody data using 
robust statistical methods. Instead of costly and time-
consuming data collection for a de-novo serological 
survey, we re-used previously collected data, minimis-
ing the costs of the study, and the burden of data col-
lection and blood sampling on families and children.
A limitation of our study is that we were not able to 
validate infection status derived from FMM against 
confirmed RSV infections, since nasopharyngeal aspi-
rates were not collected for the ALL-IN study. This 
would be useful for indicating infections in infants 
aged < 6 months, who are less likely to exhibit serologi-
cal response to infection [22-24]. Children < 6 months 
old have the highest risk of developing RSV-related 
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lower RTI [26], and their parents are therefore most 
likely to contact healthcare for their children. Therefore, 
our sensitivity analyses including children who had RTI-
related contact with healthcare at younger ages likely 
accounted for most of the early infections and showed 
consistent results. Further, we were not able to assess 
how many children were re-infected during their sec-
ond year of life. Ideally, repeated swab sampling during 
the first 2 years of life is required to estimate the rate 
of reinfection.
Our study focussed on one geographical area in the 
UK, with a multi-ethnic, urban population. Therefore, 
our results may be predominantly applicable to similar 
settings in high income countries. Our methods, how-
ever, could be applied to residual blood samples from 
other cohort studies where blood samples have been 
collected at similar intervals for comparison.
Implications
We found that over half of children in this UK study 
experienced at least one RSV infection in infancy, and 
a further third of children had evidence of primary RSV 
infection between the ages of 1 and 2 years. Our esti-
mates of the incidence of RSV in the community were 
comparable with a serological survey from Kilifi (52% 
of children were RSV-seropositive at age 12–15 months 
and 83% at age 18–24 months in 2007–2010) [27], 
higher than in a Finnish study (37% had evidence of 
infection by age 1, 68% by age 2 in 2009–2013) [15], 
and lower than the often quoted study from 1986 car-
ried out in Houston, US [14], in which 68% of 125 infants 
and 91/92 children aged 1–2 years had been infected 
with RSV. In contrast, we found that one in seven chil-
dren remained uninfected by the age of 2. These dif-
ferences could reflect differences in study settings and 
serological testing methods and performance (e.g. one 
study is now over 35 years old). Since a substantial pro-
portion of children experienced primary infection dur-
ing their second year of life, a vaccination programme 
for older infants with a catch-up school programme 
will be important in reducing the community burden 
of RSV [11]. A third of children with primary infection 
in the second year of life were in contact with primary 
care services. RSV infections in this older age group 
therefore contribute considerably to the RSV-related 
burden on health services, and should be taken into 
account in modelling studies evaluating RSV vaccina-
tion programmes.
The presence of older siblings in the household was 
the risk factor consistently predictive of the risk of pri-
mary RSV infection both in infancy and aged 2 years 
old, even after adjusting for exposure to formal child-
care environments. Older siblings, in particular school-
age older siblings, are the most likely source of RSV 
infections in households [11,13,28], and contribute to 
increased risk of RSV-related hospitalisation in young 
children [6]. Therefore, preventive strategies to reduce 
early infections in young children, whether public 
health campaigns or vaccination strategies, need to 
include reducing the risk of infection posed by older 
siblings.
Maternally-derived antibody concentrations were 20% 
lower for children born in the first half of RSV season 
(October–December) than in other months, but we did 
not observe a strong seasonal pattern as that reported 
for neutralising antibodies, with increases in mean 
RSV antibody concentrations between January–June 
and decreases thereafter [29]. We found that levels of 
maternally-derived antibodies were lower for prema-
ture babies, reflecting reduced transplacental antibody 
transfer at earlier gestations [30,31], and higher for 
mothers with older children, who are likely to introduce 
RSV infections into households [11,13,28]. Since the 
majority of RSV-related hospitalisations occur in term 
babies [6,7], our findings suggest that pregnant women 
with older children are a particularly important group 
for targeting via maternal vaccination programmes.
Conclusions
We have shown that 53% of children in England are 
infected with RSV during the first year of life, and 14% 
remain uninfected by age 2. Between birth and 2 years 
old, the proportion of RSV infected children who seek 
primary or secondary healthcare does not decrease 
with age. Our study, based on secondary analyses of 
blood samples and linked data, present a time-efficient 
and cheap method for carrying out serological surveys 
to determine the community burden of disease due to 
RSV in young children.
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